Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.53 |
| ▸ | NMBR | P28336 | 2/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.50 |
| ▸ | NPY1R | P25929 | 2/20 | 0.49 |
| ▸ | NPY2R | P49146 | 2/20 | 0.49 |
| ▸ | NPY4R | P50391 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | PRKACB | P22694 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511112 | 0.97 | GHSR (0.56) | GHSRNMBRNPY1RNPY2RNPY4R | |
| SCHEMBL30990571 | 0.97 | GHSR (0.56) | GHSRNMBRNPY1RNPY2RNPY4R | |
| SCHEMBL29641046 | 0.97 | GHSR (0.56) | GHSRNMBRNPY1RNPY2RNPY4R | |
| SCHEMBL29609515 | 0.97 | GHSR (0.56) | GHSRNMBRNPY1RNPY2RNPY4R | |
| SCHEMBL31593359 | 0.97 | GHSR (0.56) | GHSRNMBRNPY1RNPY2RNPY4R | |
| SCHEMBL29790169 | 0.97 | GHSR (0.56) | GHSRNMBRNPY1RNPY2RNPY4R | |
| SCHEMBL29790108 | 0.97 | GHSR (0.56) | GHSRNMBRNPY1RNPY2RNPY4R | |
| SCHEMBL29609768 | 0.97 | GHSR (0.56) | GHSRNMBRNPY1RNPY2RNPY4R | |
| SCHEMBL29484173 | 0.97 | GHSR (0.56) | GHSRNMBRNPY1RNPY2RNPY4R | |
| SCHEMBL30085020 | 0.97 | ACE (0.52) | GHSRERAP2ERAP1LNPEPNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025245292-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT LOSS | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025245288-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20240182519-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2024-06-06 | — | — | US | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182519-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | GHSR 102/4885NMBR 133/4885ERAP2 773/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | GHSR 33/4885NMBR 138/4885ERAP2 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.